CASE STUDY ONE: FUSION
To help you understand what we mean by Courageous research, we have created a series of case studies, outlining how we have solved unconventional business challenges with a breath of fresh air.
THE BRIEF
Are infusion clinics really boring, stressful and time-consuming? The client wanted to be the market leader in biologics in gastroenterology. They had an in-home sub-cutaneous treatment while the standard of care was a hospital-administered infusion product.
Watch the video for Case Study One: Fusion
Curious to know how we solved this brief?
Send us an email and we will tell you all about our courageous methodology. Also find out more about our courageous workshops, where we come to you in person and show you why being courageous researchers is so important.
Watch the video for Case Study Two: Keystone
Curious to know how we solved this brief?
Send us an email and we will tell you all about our courageous methodology. Also find out more about our courageous workshops, where we come to you in person and show you why being courageous researchers is so important.
CASE STUDY TWO: KEYSTONE
To help you understand even further what we mean by Courageous research, this is our Case Study Two: Keystone.
THE BRIEF
Our client had a portfolio of tumour markers competing with other investigations for use in oncology diagnosis and treatment monitoring. The research objective was to decide whether to continue to focus their sales efforts on clinical scientists or change direction targeting physicians, and, if so, which ones and how to best approach them.
Recreating the setting in which management and treatment decisions for lung cancer are made gave us the opportunity to understand first-hand the chain of events and the decision making process for biomarker testing, observing interactions and power relationships, identifying the key stakeholder in diagnostic and monitoring as well as involving clinical scientists in order to understand whether they have the knowledge, the ability to influence and the willingness to proactively take an educational role with physicians’ counterparts on how to use tumour markers.
The multi-phased methodology we designed for this study is particularly suited to real life situations where HCPs consult with each other as well as with external counterparts to make important treatment decisions.
